

LAB ALERT - ANNOUNCEMENT
REPLACEMENT OF DISCONTINUED TEST:

DISCONTINUED TEST: FRAGILE X (FMRI) SCREEN WITH REFLEX TO FRAGILE X (FMRI) DIAGNOSTIC
REPLACEMENT: FRAGILE X (FMRI) WITH REFLEX TO METHYLATION ANALYSIS

NOTIFICATION DATE: 1/2/2014
EFFECTIVE DATE: 1/6/2014

DISCONTINUED TEST CODE:	FXSCR
DISCONTINUED INTERFACE CODE:	1003826
REPLACEMENT TEST:	<i>FRAGILE X (FMRI) WITH REFLEX TO METHYLATION ANALYSIS</i> <i>FORMERLY NAMED: FRAGILE X (FMRI) DIAGNOSTIC</i>
REPLACEMENT TEST CODE:	FXD
REPLACEMENT INTERFACE CODE:	1003827
ANNOUNCEMENT:	<p>The original reflex test (code FXSCR) has been discontinued.</p> <p>The currently available test Fragile X (FMRI) Diagnostic will be the replacement test and will now include the screen as well as the original diagnostic Methylation Analysis.</p> <p>In addition, the name of the test code FXD has been updated to <i>FRAGILE X (FMRI) WITH REFLEX TO METHYLATION ANALYSIS</i> to indicate the test modification. All other test requirements, information, and interface build is unchanged for FXD</p>
PERFORMING LAB:	ARUP Laboratories
ORDER/CONTACT INFORMATION:	Thomas P. Lohmann, MD, Chief Medical Officer, 972-966-7135 or ClearPoint Client Services: 972-966-7700/Fax: 972-966-7799



Thomas P. Lohmann, MD
 Chief Medical Officer